Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Safety and Efficacy Study of ADI-001 Anti-CD20 CAR-engineered Allogeneic Gamma Delta (γ??) T Cells in Adults With B Cell Malignancies

Next Previous
Trial Profile

A Phase 1 Safety and Efficacy Study of ADI-001 Anti-CD20 CAR-engineered Allogeneic Gamma Delta (γ??) T Cells in Adults With B Cell Malignancies

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 25 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ADI-001 (Primary) ; Cyclophosphamide; Fludarabine
  • Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; First in man
  • Acronyms GLEAN study; GLEAN-1
  • Sponsors Adicet Bio

Most Recent Events

  • 18 Jun 2025 Status changed from active, no longer recruiting to discontinued.
  • 06 Nov 2024 According to an Adicet Bio media release, data from the study will be presented as an oral abstract highlighting previously presented ADI-001 clinical biomarker data at ACR Convergence 2024 taking place November 14-19 in Washington, D.C.
  • 19 Sep 2024 According to an Adicet Bio media release, data from the study were presented at the 9th Annual CAR-TCR Summit on Thursday, September 19, 2024 in Boston, MA.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top